Engflag

Asonor

Quick links to important sections

Asonor

Asonor_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asonor

Quick Facts

Property Description
Active ingredient Glycerol, Sodium Chloride
Form Nasal spray, Solution
Pharmacological class Humectant, Lubricant, Mechanical decongestant
Common use Relief of habitual snoring
Origin Components are high-purity synthetic grade

Asonor: Definition, Drug Form, and General Purpose

Asonor is a specialized, non-systemic preparation delivered as an aqueous solution via a nasal spray for the purpose of alleviating habitual snoring. Its classification places it among aids intended for Adults whose snoring is caused by vibrations in the upper airway tissue, making it a locally acting intervention.

The product's general purpose is to support air passage integrity and reduce the source of nocturnal noise. The formulation is intended to modify the physical characteristics of the upper airway tissue, separating it from systemic medications that alter body function via absorption. The nasal spray drug form allows for targeted delivery to the pharynx, differentiating it from oral or mandibular devices.

Composition and Pharmacological Classification

Asonor is a combination product formulated with specific chemical substances, principally the active ingredients Glycerol and Sodium Chloride. Its classification as a Humectant and Lubricant is achieved by incorporating Glycerol 85% alongside saline components like Sodium Chloride (e.g., Conc Nacl 0.9%).

This composition leverages the physical properties of the ingredients; Glycerol possesses hygroscopic qualities and acts as an osmotic agent. Furthermore, the inclusion of Sodium Chloride in nasal preparations is intended to aid in moisturizing the nasal passages and supporting the clearance of irritants.

The Core Mechanism Principle for Snoring Relief

The product’s function is based on the physiological action of simultaneously lubricating the pharyngeal tissue and inducing a temporary firmness. Asonor achieves this through the osmotic mechanism of Glycerol, which influences the water content within the tissue.

This principle focuses on reducing the noise generated during sleep. By achieving this combination of stiffening of the tissue and lubrication of the mucous membranes, the mechanism of effect targets the vibrations in the soft palate that are the source of snoring.

Regulatory References

  1. NIH Saline Literature

What side effects are possible with Asonor?

Possible Side Effects and Safety Information

The safety profile for Asonor is established by its regulatory classification and official warnings, which strictly define its appropriate use and limitations.

Adverse Reaction Summary

Official regulatory-compliant clinical testing has not detected any adverse effects following treatment with Asonor. Consequently, a frequency classification for side effects (such as Common, Uncommon, or Rare) is currently designated as Not Known.

Adverse Reaction Scope Regulatory Statement
Adverse Reactions Detected None detected in clinical testing.
System-Organ Classes None were identified or detected.

Safety Restrictions and Limitations

Official government-mandated safety information defines specific conditions and groups for which use is restricted:

  • Contraindications (Allergies): The product must not be used by individuals with a known allergy or hypersensitivity to any of its listed ingredients, such as Polysorbate 80, Glycerol 85%, or Sodium Chloride.
  • Sleep Apnea Exclusion: The product is explicitly not a treatment for obstructive sleep apnea (OSA). Individuals experiencing persistent severe symptoms, such as heavy snoring, tiredness, morning headaches, or dizziness, must consult a physician to rule out this condition.
  • Pediatric Safety: Administration to individuals under the age of 18 is restricted to use only under adult supervision.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory safety assessment for Asonor indicates that the product is considered practically non-toxic, and no systemic toxicity is expected following excessive exposure. This classification is based on evaluations, primarily using the European regulatory framework (EC 1272/2008).

Documented Overexposure Manifestations and Emergency Actions

Overexposure Route Expected Effect (Regulatory Statement) Required Emergency Action
Ingestion Considered non-toxic; practically non-toxic. First aid is not normally required.
Inhalation Considered non-toxic; practically non-toxic. First aid is not normally required.
Eye Contact May cause mild irritation. Immediately flush eyes with plenty of water for at least 2 minutes.
Skin Contact Not expected to cause skin irritation. First aid is not normally required.

When to Seek Medical Help

Regulatory documentation does not contain explicit statements requiring a call for emergency medical help (e.g., 911) for suspected ingestion or inhalation of excessive amounts due to the non-toxic classification. The official guidance emphasizes that in case of contact with the eyes, the affected area must be immediately flushed for a minimum of two minutes. For any concern about a severe reaction or if irritation persists after immediate flushing, a medical professional should be consulted. Healthcare providers treating a possible overexposure are generally advised to manage symptoms, as no specific antidote is known or required.

Therapeutic Uses of Asonor

Asonor is commonly used to help manage the symptoms related to habitual snoring, a condition linked to physical changes in the upper airway tissues. As a supportive product, it is relevant for helping to reduce the overall symptom load of non-apneic snoring. The therapeutic focus is on providing supportive relief from acoustic disturbance and associated physical discomfort.

Quick Fact: Relief for Habitual Snoring

Focus Benefit Category
Symptom Type Nocturnal Acoustic Disturbance
Therapeutic Goal Easing of throat dryness and irritation
Primary Use Daily symptomatic management in adults

This product is relevant for managing symptom clusters that create noticeable physiological strain and may interfere with daily functioning, making it applicable within clinical settings that involve recurrent or episodic symptom patterns. Asonor is commonly used to help manage the symptoms related to nocturnal acoustic disturbance (loud snoring) and pharyngeal tissue discomfort (throat dryness). This approach supports general well-being by offering simple, supportive relief for chronic nighttime noise, which may assist with maintaining functional stability for the user and their partner.

Regulatory References

  1. NIH MedlinePlus overview on Snoring

Eligibility and Restrictions for Use

Asonor is a nasal preparation regulated as a medical device in many jurisdictions, and its eligibility profile is defined by specific exclusions and population restrictions stated in regulatory documents.

Contraindications and Eligibility

Category Official Regulatory Status
Absolute Contraindications Contraindicated in individuals with a known allergy or hypersensitivity to any of the product's ingredients.
Clinical Restriction Not a treatment for Obstructive Sleep Apnea (OSA). If severe snoring is accompanied by persistent symptoms like tiredness, headache, or dizziness, users should consult a physician to rule out OSA.
Age Restriction Individuals under 18 years of age should use the product only under adult supervision.
Pregnancy/Lactation Generally considered safe for use by pregnant and breastfeeding women, though pregnant users are advised to consider consulting a doctor before use.

These official statements define who is prohibited from using the product (those with hypersensitivity) and who requires specific conditions for use (minors and individuals with symptoms suggesting OSA). The product is intended for adults experiencing simple snoring and is not classified as a definitive medical treatment for sleep disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Asonor defines its interaction profile based on the product’s non-systemic, locally applied action as a nasal solution. This profile is characterized by the absence of systemic interaction findings.

No formal systemic pharmacokinetic interactions are documented in government regulatory sources. This finding aligns with the product's local mode of action, meaning the regulatory information does not list specific medicinal products or substance categories that are contraindicated or require dose adjustment based on systemic metabolic enzyme activity, such as CYP-mediated effects, or drug transporter mechanisms.

Similarly, there are no documented pharmacodynamic interactions, which means no additive or synergistic effects with co-administered medicinal products are specified in regulatory labels. No population-specific interaction considerations are listed, for instance, for patients with hepatic or renal impairment.

The only official constraint documented is an administration-timing restriction. This rule requires the user to avoid consuming food, drinking beverages, or brushing their teeth immediately following application. This procedural constraint is in place to preserve the solution’s coating on the pharyngeal tissue, ensuring the intended local physical action can take place.

Mechanism of Action

Mechanism of Asonor Action

Asonor's mechanism of action is focused on the modulation of biological processes within relevant physiological systems, resulting in targeted adjustments in pathway activity. Its pharmacodynamic effects are channeled through distinct mechanistic domains, describing how the substance interacts at the cellular level.

Modulation of Specific Molecular Mediator Activity

Asonor engages mechanisms that modulate the activity of specific molecular mediators affecting physiological responses. This action involves influencing the initiation or suppression of signaling sequences at early molecular steps, thereby influencing downstream physiological consequences and specific cellular events.

Targeted Pathway Adjustment of Signaling Activity

Within specific domains, Asonor acts to alter pathway activity by interacting with signaling patterns that may fluctuate under certain conditions. This interaction is relevant in systems requiring targeted adjustment of signaling, resulting in specific physiological adjustments and pathway modulation.

Influence on Feedback Signaling within Pathways

The substance influences feedback regulation within the targeted pathways. This involves modifying signaling steps and modulating the regulation of processes driven by distinct signaling patterns, ultimately influencing pathway dynamics and sustained signaling patterns.

Dosage and Administration Information

How Asonor is Used

Official guidelines for Asonor Nasal Spray focus on a precise topical application regimen designed to ensure the solution reaches the pharyngeal tissue, which is the site of action.

Administration Protocol

The product is designated for nasal application and is delivered as a solution via a nasal spray device. The intended target area is not the nasal passages, but the throat; application requires the user to tilt the head back and continue pumping until the solution is felt in the throat.

Feature Official Labeled Instruction
Route of Administration Nasal application
Standard Dose 4 to 6 pumps per nostril per dose
Frequency Once daily, every evening before bedtime

Timing and Procedural Constraints

The established dosing schedule requires administration every evening before bedtime to coincide with the period of nocturnal snoring. A crucial procedural constraint is the instruction to avoid eating, drinking, or brushing teeth immediately following the application. This is structurally defined to maintain the solution’s presence on the pharyngeal mucous membranes.

Duration and Specific Populations

Asonor is intended for consistent, long-term daily use for symptomatic management. While designed for adult use, the instructions specify that individuals under 18 years of age should use the product only under adult supervision. If a dose is missed, the regimen advises simply resuming the application the next evening.

Recent Clinical Evidence

Asonor: Recent Clinical Evidence

Research Focus on Components

Current research indicates that Asonor is a fixed-dose combination solution. The primary components include Polysorbate 80, Glycerol (Glycerin), and Sodium Chloride (Saline). These ingredients are categorized as surfactants and osmotic agents, which are subjects of ongoing research regarding their potential influence on the tissues of the upper airway.

Summary of Clinical Findings

Findings from available studies vary. Clinical studies have investigated whether the use of the solution was associated with a reduction in the severity or frequency of snoring in participants. Research has also explored comparisons to single-ingredient or placebo options.

Study Type Primary Focus Outcome Measured
Phase 3 RCT (Example) Change in symptom severity over a 12-week period. Change in Symptom Assessment Score (SAS) from baseline.
Observational Cohort (Example) Long-term patterns of usage and symptom frequency. Participant-reported quality of life metrics over 12 months.
Meta-analysis (Example) Pooled data from independent trials on the solution. Change in reported pain levels across different subgroups.

Key Considerations for Research Interpretation

The compounds used in this approach are subjects of ongoing research regarding their potential influence on symptoms associated with the target condition. This information is intended solely to describe the scope of research conducted on the product and should not be construed as clinical guidance.

Frequently Asked Questions (FAQ)

Common questions about Asonor (FAQ)

Q: What should I do if Asonor gets in my eyes?

A: Official product safety guidance directs users to avoid spraying the solution toward the eyes. If contact occurs, rinsing the eyes thoroughly with clean water is generally recommended in product safety guidance.

Q: Can I use Asonor with other nasal sprays or cold medicines?

A: Official documentation indicates that no formal systemic pharmacokinetic interactions—meaning how the body handles the product—are documented. However, the product label does not contain specific studies on co-administering Asonor with other topical nasal products or cold medicines. As with any combination of products, it is advisable to discuss potential interactions with a healthcare professional.

Q: Does Asonor interact with alcohol?

A: The official product label does not list any formal systemic interactions with alcohol. However, alcohol is widely known to relax the muscles in the throat, which can sometimes worsen habitual snoring. Official guidance suggests that users may wish to avoid consuming alcohol immediately before bedtime, as alcohol can worsen snoring.

Q: Is Asonor safe to use during pregnancy or while breastfeeding?

A: Product information indicates Asonor is generally intended for use by pregnant and breastfeeding women. However, the official product label advises that pregnant users consider consulting a doctor prior to using the product.

Q: How do I prime the Asonor bottle for first use?

A: Official instructions focus on tilting the head back and continuing to pump until the solution is felt in the throat. This procedure is the standard application method, which also prepares the spray for use.

How should Asonor be stored and disposed of?

How to Store and Dispose of Asonor

Official regulatory information defines specific environmental and stability requirements necessary to maintain the integrity and safety of Asonor nasal spray.

Storage Requirements

Item Requirement
Temperature Store between 5 C and 25 C (41 F to 77 F); do not expose to temperatures exceeding 50 C.
Protection Keep the product out of direct sunlight and store in the original container.
Child Safety Must be kept out of the sight and reach of children and pets.

Stability and Disposal

The product must be used within 3 months of opening and must not be administered after the package expiry date. Unused or expired Asonor must be handled as special waste and disposed of strictly in compliance with all local and national regulations. This prevents environmental contamination and ensures proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Asonor found in:

A-Z Index: